Home›Research›Compare›CJC-1295 vs GHRP-2
Peptide Comparison
CJC-1295 vs GHRP-2
Both are GH / IGF Axis peptides.
CJC-1295
CJC-1295 DAC
Half-life: 6–8 days (DAC form)
445 providers listed
GHRP-2
Growth Hormone Releasing Peptide 2
Half-life: 15–60 minutes
42 providers listed
Bottom line
CJC-1295 carries stronger published evidence (RCT, 2 key studies) than GHRP-2 (Cohort study, 2); both are research compounds.
Quick Verdict
CJC-1295
Evidence
Half-life
6–8 days (DAC form)
GHRP-2
Evidence
Half-life
15–60 minutes
Which One Should You Choose?
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | CJC-1295 |
| Less frequent dosing (longer half-life) | CJC-1295 |
| Lower typical price per mg | GHRP-2 |
| More provider options (445 vs 42) | CJC-1295 |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Side-by-Side Comparison
Research Evidence
CJC-1295
GHRP-2
Research Citations
CJC-1295
About CJC-1295
CJC-1295 binds to and activates pituitary GHRH receptors, stimulating pulsatile GH secretion. The DAC modification enables covalent binding to albumin, dramatically extending the active peptide half-life. This sustained GH pulse pattern is intended to mimic physiological GH release more closely than shorter-acting GHRH analogues.
Research Areas
About GHRP-2
Synthetic hexapeptide that stimulates pulsatile growth hormone release from the anterior pituitary by acting on the ghrelin receptor (GHSR-1a). Commonly stacked with GHRH analogs such as CJC-1295 or Sermorelin to amplify GH output synergistically.
Research Areas
Safety Profile
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
CJC-1295
Contraindications
Suggested Monitoring
Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.
GHRP-2
Contraindications
Suggested Monitoring
GHRP-2 stimulates GH and cortisol release. Research protocols measure IGF-1 for GH axis response and baseline cortisol given the compound's adrenal stimulation. Glucose markers are standard given GH's effect on insulin sensitivity.
Used Together?
CJC-1295
Ipamorelin
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.
GHRP-2
Corticosteroids
Research notes that GHRP-2 stimulates cortisol and ACTH release via the HPA axis. Combined use with corticosteroid medications may affect glucocorticoid regulation. Consult your prescriber before combining.
Price (per mg)
CJC-1295
GHRP-2
Find Providers
Where to source these peptides
Providers offering
CJC-1295
445 listed
Browse directory →
Providers offering
GHRP-2
42 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More GH / IGF Axis Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 3, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). CJC-1295 vs GHRP-2 — Per-mg Price Comparison. Retrieved July 5, 2026, from https://peptidebase.io/peptides/compare/cjc-1295/ghrp-2